...BRCA1, RAD51AP1, NBN, PNKP, TP53BP1, and PBRM1. UALCAN analysis further revealed differential regulation of SMG1 phospho...
...BRCA1/2 testing was negative. She underwent four cycles of neoadjuvant doxorubicin/cyclophosphamide with limited respons...
...BRCA1/2-mutant tumors, has emerged as an effective strategy for cancer therapy. GEN1, a structure-selective endonuclease...
...BRCA1 being particularly prominent. Immunologically, LOLC tumors exhibited higher TMB and PD-L1 positivity. Integrated p...
...BRCA1/2 mutations, where further failure of DNA repair results in cell sensitization. Building on the concept of synthet...
...BRCA1/2 mutations. However, not all patients respond to these drugs, and therapy-predictive biomarkers are needed to opt...
...BRCA1. These genes are involved in the molecular pathway of DNA repair by homologous recombination (HRD). Our results de...
...BRCA1 and BRCA2 deficiency. Homologous recombination (HR)-deficient tumors upregulate DDIAS to enable HR-deficient cells...
...BRCA1-/BRCA2-deficient cells. We also identify biallelic inactivating mutations in DDIAS in patients with a severe neuro...
...BRCA1/2 or PALB2 variants. Biliary tract cancer is therefore a clinically useful model for precision oncology: anatomica...
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话: 0531-88819269